Skip to content

Repligen RGEN Stock options excluded as their inclusion would be anti-dilutive (in shares)

Stock options excluded as their inclusion would be anti-dilutive (in shares) at other companies

Charles River Laboratories logo
Charles River LaboratoriesCRL
615K-35.8%
Revvity logo
RevvityRVTY
Thermo Fisher Scientific logo
Thermo Fisher ScientificTMO
Bio-Rad Laboratories logo
Bio-Rad LaboratoriesBIO

Other financials

Income statement

See full
Revenue$194.3M+14.8%
Gross profit$108.3M+18.5%
Operating income$15.9M+142%
Net income$8.3M+42.9%
EPS (diluted)$0.15+50.0%

Balance sheet

See full
Cash & equivalents$582.7M-16.4%
Total debt$687.6M+346%
Total equity$2.1B+6.0%
Total assets$2.9B+2.8%

Cash flow

See full
Operating cash flow$28.3M+88.6%
CapEx$4.7M+32.2%
Free cash flow$23.6M+106%

Valuation

See full
Market cap$7.45B-7.1%
Enterprise value$7.55B+2.1%
P/E144.9×
P/S10.1×-0.1×

Profitability

See full
Gross margin49.5%+2.7pp
Operating margin1.5%-14.0pp
Net margin17.1%-3.7pp
FCF margin21.2%+6.1pp

Returns & leverage

See full
Return on equity2.5%+1.9pp
Debt / equity0.3×+0.2×
Current ratio9.2×+2.4×

Where this comes from

Reported directly by Repligen in its filing.

Tagged under the XBRL concept us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount.

The official record: Repligen’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Repligen's stock options excluded as their inclusion would be anti-dilutive (in shares).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Repligen's stock options excluded as their inclusion would be anti-dilutive (in shares)?
Repligen (RGEN) reported stock options excluded as their inclusion would be anti-dilutive (in shares) of 520K in Q1 2026.
How has Repligen's stock options excluded as their inclusion would be anti-dilutive (in shares) changed year-over-year?
Repligen's stock options excluded as their inclusion would be anti-dilutive (in shares) increased by 27.1% year-over-year, from 409K to 520K.
What is the long-term trend for Repligen's stock options excluded as their inclusion would be anti-dilutive (in shares)?
Over 2 years (2021 to 2023), Repligen's stock options excluded as their inclusion would be anti-dilutive (in shares) has grown at a 118.8% compound annual growth rate (CAGR), from 277.5K to 1.3M.
What does stock options excluded as their inclusion would be anti-dilutive (in shares) mean?
The total number of potential common shares, such as stock options or convertible debt, excluded from the diluted earnings per share calculation because their inclusion would increase earnings per share or decrease loss per share. This metric helps investors identify potential future dilution that is currently excluded due to anti-dilutive effects.